Imidazoline I1 receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 102-105

  Tanabe, Mitsuo ^a   Hashimoto, Masako ^a   Ono, Hideki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Electromyogram; Imidazoline receptor; Moxonidine; Parkinson's disease; Rigidity; Tizanidine

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; EFAROXAN; IDAZOXAN; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I1 RECEPTOR AGONIST; IMIDAZOLINE I1 RECEPTOR ANTAGONIST; IMIDAZOLINE I2 RECEPTOR ANTAGONIST; LIGAND; MOXONIDINE; RESERPINE; TIZANIDINE; YOHIMBINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; LIGAND BINDING; MALE; MOTOR DYSFUNCTION; MOUSE; MUSCLE RIGIDITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BENZAZEPINES; BENZOFURANS; CLONIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; IDAZOXAN; IMIDAZOLES; IMIDAZOLINE RECEPTORS; INJECTIONS, INTRAPERITONEAL; LIGANDS; MALE; MICE; MUSCLE RIGIDITY; MUSCLE, SKELETAL; PARKINSONIAN DISORDERS; RESERPINE; TIME FACTORS; YOHIMBINE;

EID: 47549104255     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.013     Document Type: Article

References (23)

1. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13 (1990) 266-271
2. Anderson R.J. Modification of reserpine induced rigidity by dopaminergic and alpha-adrenergic drugs. Acta. Neurol. Scand. 72 (1985) 584-589
3. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul H., Ladure P., Rascol O., and Gross C.E. Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 1237-1246
4. 2-imidazoline ligands. Br. J. Pharmacol. 125 (1998) 175-185
5. 2-Adrenoceptor antagonists: a new approach to Parkinson's disease?. CNS Drugs 10 (1998) 189-207
6. Bricca G., Dontenwill M., Molines A., Feldman J., Tibirica E., Belcourt A., and Bousquet P. Rilmenidine selectivity for imidazoline receptors in human brain. Eur. J. Pharmacol. 163 (1989) 373-377
7. Di Chiara G., Morelli M., and Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17 (1994) 228-233
8. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., and Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19 (1998) 381-390
9. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 264 (1993) 172-182
10. 1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann. NY Acad. Sci. 763 (1995) 22-42
11. 2-adrenoceptors in rat brain membranes. Arzneimittelforschung 38 (1988) 1442-1445
12. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15 (1992) 133-139
13. Honda M., Sekiguchi Y., Sato N., and Ono H. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. Eur. J. Pharmacol. 445 (2002) 187-193
14. Kino Y., Tanabe M., Honda M., and Ono H. Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes. J. Pharmacol. Sci. 99 (2005) 52-60
15. 2 binding sites in mouse brain. Eur. J. Pharmacol. 516 (2005) 139-144
16. 1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 279 (1996) 694-702
17. Prell G.D., Martinelli G.P., Holstein G.R., Matulić-Adamić J., Watanabe K.A., Chan S.L., Morgan N.G., Haxhiu M.A., and Ernsberger P. Imidazoleacetic acid-ribotide: an endogenous ligand that stimulates imidazol(in)e receptors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13677-13682
18. Ruggiero D.A., Regunathan S., Wang H., Milner T.A., and Reis D.J. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. 780 (1998) 270-293
19. 2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 629-638
20. 1-imidazoline receptors reduce GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 26 (2006) 1795-1802
21. Wagner B.H., and Anderson R.J. Prevention of reserpine rigidity by alpha-2 adrenergic antagonists. Pharmacol. Biochem. Behav. 16 (1982) 731-735
22. Wallenstein S., Zucker C.L., and Fleiss J.L. Some statistical methods useful in circulation research. Circ. Res. 47 (1980) 1-9
23. 1)-receptor-mediated hypotension. J. Pharmacol. Exp. Ther. 314 (2005) 945-952